Intranasal dexamethasone: a new clinical trial for the control of inflammation and neuroinflammation in COVID-19 patients.
Graciela CárdenasMaría Chávez-CanalesAna María EspinosaAntonio Jordán-RíosDaniel Anica MalagonManlio Fabio Márquez MurilloLaura Victoria Torres AraujoRicardo Leopoldo Barajas CamposRosa María Wong-ChewLuis Esteban Ramirez GonzálezKarent Ibet CresencioEnrique García VelázquezMariana Rodriguez de la CerdaYoana LeyvaJoselin Hernández-RuizMaría Luisa Hernández-MedelMireya León-HernándezKaren Medina QueroAnahí Sánchez MonciváisSergio Hernández DíazIgnacia Rosalia Zeron MartínezAdriana Martínez-CuazitlIván Noé Martínez SalazarEduardo Beltrán SarmientoAldo Figueroa PeñaPatricia Saraí HernándezRafel Ignacio Aguilar ReynosoDaniela Murillo ReyesLuis Rodrigo Del Río AmbrizRogelio Antonio Alfaro BonillaJocelyn CruzLeonor HuertaNora Alma FierroMarisela HernándezMayra Pérez-TapiaGabriela MenesesErick Espíndola-ArriagaGabriela RosasAlberto ChinneySergio Rosales MendozaJuan Alberto Hernández-AcevesJaquelynne Cervantes-TorresAnai Fuentes RodríguezRoxana Olguin AlorSandra Ortega FranciscoEvelyn Alvarez SalazarHugo BesedovskyMarta C RomanoRaúl J BobesHelgi JungGloria SoldevilaJuan López-AlvarengaGladis FragosoJuan Pedro LacletteSciutto EddaPublished in: Trials (2022)
ClinicalTrials.gov NCT04513184 . Registered November 12, 2020. Approved by La Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) with identification number DI/20/407/04/36. People are currently being recruited.
Keyphrases
- clinical trial
- oxidative stress
- sars cov
- traumatic brain injury
- low dose
- lipopolysaccharide induced
- high dose
- lps induced
- phase ii
- double blind
- study protocol
- cognitive impairment
- open label
- drug administration
- bioinformatics analysis
- cerebral ischemia
- randomized controlled trial
- phase iii
- cystic fibrosis
- pseudomonas aeruginosa
- subarachnoid hemorrhage